These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26678026)

  • 1. A taxonomy of estimands for regulatory clinical trials with discontinuations.
    Permutt T
    Stat Med; 2016 Jul; 35(17):2865-75. PubMed ID: 26678026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity analysis for missing data in regulatory submissions.
    Permutt T
    Stat Med; 2016 Jul; 35(17):2876-9. PubMed ID: 26567763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing estimands in clinical trials with missing data.
    Mallinckrodt C; Molenberghs G; Rathmann S
    Pharm Stat; 2017 Jan; 16(1):29-36. PubMed ID: 27492760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A regulatory perspective on missing data in the aftermath of the NRC report.
    LaVange LM; Permutt T
    Stat Med; 2016 Jul; 35(17):2853-64. PubMed ID: 26677837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimands in published protocols of randomised trials: urgent improvement needed.
    Kahan BC; Morris TP; White IR; Carpenter J; Cro S
    Trials; 2021 Oct; 22(1):686. PubMed ID: 34627347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.
    Ocampo A; Bather JR
    Stat Med; 2023 Sep; 42(21):3892-3902. PubMed ID: 37340887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
    Mehrotra DV
    Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
    Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
    Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Starting a conversation about estimands with public partners involved in clinical trials: a co-developed tool.
    Cro S; Kahan BC; Patel A; Henley A; C J; Hellyer P; Kumar M; Rahman Y; Goulão B
    Trials; 2023 Jul; 24(1):443. PubMed ID: 37408080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
    Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
    Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods.
    Olarte Parra C; Daniel RM; Bartlett JW
    Stat Biopharm Res; 2023; 15(2):421-432. PubMed ID: 37260584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
    Qu Y; Shurzinske L; Sethuraman S
    Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimands in clinical trials - broadening the perspective.
    Akacha M; Bretz F; Ruberg S
    Stat Med; 2017 Jan; 36(1):5-19. PubMed ID: 27435045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disentangling estimands and the intention-to-treat principle.
    Leuchs AK; Brandt A; Zinserling J; Benda N
    Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Lynggaard H; Keene ON; Mütze T; Rehal S
    Pharm Stat; 2024 Aug; ():. PubMed ID: 39115134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing Appropriate Estimands in Clinical Trials.
    Leuchs AK; Zinserling J; Brandt A; Wirtz D; Benda N
    Ther Innov Regul Sci; 2015 Jul; 49(4):584-592. PubMed ID: 30222440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments on "A taxonomy of estimands for regulatory clinical trials with discontinuations".
    Doi M; Watanabe D; Takenouchi K; Tsuchikawa M
    Stat Med; 2017 Nov; 36(27):4414-4416. PubMed ID: 29110371
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimands: discussion points from the PSI estimands and sensitivity expert group.
    Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
    Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
    Phillips A; Clark T
    Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.